Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
about
Receptor for advanced glycation end products and its involvement in inflammatory diseasesIntegrated network analysis of transcriptomic and proteomic data in psoriasisSoluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and functionDangers within: DAMP responses to damage and cell death in kidney disease.The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculatureSoluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and agingLong-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerEndogenous secretory receptor for advanced glycation end products and chronic kidney disease in the elderly population.Dynamic and extensive metabolic state-dependent regulation of cytokine expression and circulating levelsReceptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cellsChronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptorSoluble receptor for advanced glycation end products as an indicator of pulmonary vascular injury after cardiac surgerySerum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairmentSoluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.HMGB1/RAGE Signaling and Pro-Inflammatory Cytokine Responses in Non-HIV Adults with Active Pulmonary Tuberculosis.Association of genetic variants in the receptor for advanced glycation end products gene with diabetic retinopathy: A meta-analysis.A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway.Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling.Atherosclerosis and the Hypercholesterolemic AGE-RAGE AxisReactive metabolites and AGE-RAGE-mediated inflammation in patients following liver transplantationHMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms.RAGE biology, atherosclerosis and diabetes.Platelet activation in obesity and metabolic syndrome.The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus.Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?Therapeutic targets for rheumatoid arthritis: Progress and promises.Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction.Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study.The S100B/RAGE Axis in Alzheimer's Disease.Increase of Soluble RAGE in Cerebrospinal Fluid following Subarachnoid Haemorrhage.Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection.Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD.Hypoxia, receptor for advanced glycation end products, and cystic fibrosis: a pathway to chronic inflammation?
P2860
Q21285070-087272F8-E9E4-4C2A-8020-BCB1EF6B8588Q24610642-C2E64F4B-8FF0-450C-AAFC-4573A628F8E4Q27319831-48D5553E-E890-4F3B-BA0A-E5C76DB0322EQ28286769-48EF0826-1F45-439C-BE45-B0F1543BD2D4Q30380000-C1AE2357-7E0F-4346-A5F3-DB3C33B93F09Q33822512-DDF86DB9-8555-46E1-BEFC-03F9AF49CF1BQ34094369-47C6E714-A7B4-4F3E-AFF5-4FD3501A41CCQ34608976-CAA5B08E-1D16-4BB0-8C74-F24E11EC142BQ34724954-4F8A7AA9-BDA5-40DF-83F3-7E0DC8CB069EQ34726647-AAD3CBDD-0571-4CAE-8810-743CC9C7ADE1Q34797370-6F03D0FC-EE61-47EE-85C2-1F2E3AEA411AQ35002122-7BEC08AB-6D75-4AB2-85D7-BFDC57C89336Q35068413-139767ED-19B4-4A9C-BDC4-C50C4DE8BFE0Q35563671-064C032E-9011-4C39-9503-9C1E1D5C23C3Q35746399-75F40B39-5BD5-4712-BE23-C95ED5665DBFQ36081780-1CD92769-910F-48DE-BEA5-9DC8A4A625ECQ36148134-82B422F7-553B-40E7-93C0-27EE748DACA7Q36321887-686522F3-06F1-467F-A33D-A4C6E61ABDD2Q36661845-90DFA30F-390B-4D18-9EE5-202C81FDE1C1Q36909193-E068BE7C-B647-4090-9F40-ECB46FAF3A08Q36916192-6BC7F47E-A974-424F-9AF1-8D854D5224C8Q37199557-F2135F20-3E56-4F00-B940-EFF2F7E32349Q37673703-0D1F335A-1B98-4592-A31C-060D0C2303B4Q37860348-E412E2B8-D74B-46B0-88CB-DB1771D06AB3Q37932076-330B92AF-598F-4B8F-B6AF-5F87C8833F35Q38131032-D16488DA-7163-4811-9C01-1CD0B3C9550EQ38150990-350EC280-97AA-4E9F-B1B9-59DD9EBD4ED7Q38179461-419D8E6A-4B4F-4B03-ACD4-AE67FB77E9FCQ38430098-11BD4D8A-D588-4744-81FD-7A0CE5127658Q38686477-544A5A18-145E-4BDD-BBB8-BF2F812FAED7Q39095935-69C26913-FCE7-41D0-AA16-07DD75ACA426Q39313922-8365C383-EDA5-4FC5-A296-59194898E9FDQ40127796-D9C303CF-52DB-45B8-A3CB-FC5CDED53682Q41253670-273A69B2-2401-4F09-88DE-44DBA13E4C37Q42151789-EF9C269E-1D48-4001-87EA-071FAA487C22Q42177725-F4403E69-CF3A-4555-86D1-AA2F25A9ADCDQ42537047-6D843598-1A19-46FE-89F1-8074CF03A538Q42575063-896E243A-861B-4AF8-B429-FA29A58E2ADBQ43633176-A92DB52A-4D42-4241-A3D1-1D6CA969C597Q45031309-4A4DE135-99BD-43A9-82E1-B195851D4925
P2860
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@en
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@nl
type
label
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@en
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@nl
prefLabel
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@en
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@nl
P2093
P1476
Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
@en
P2093
Francesca Santilli
Giovanni Davì
Loredana G Bucciarelli
Natale Vazzana
P304
P356
10.2174/092986709787581888
P577
2009-01-01T00:00:00Z